A new study has demonstrated proof of concept for a Biolinq continuous sensor in preventing muscle loss during GLP-1 therapy.
Investigators presented findings as a late-breaking poster at the American Diabetes Association’s 85th Scientific Sessions in Chicago.
Using a DNA-based bioreceptor (aptamer), Biolinq designed its sensor to detect phenylalanine, an essential amino acid. Released from skeletal muscle breakdown and exogenous protein ingestion, it serves as a key marker, according to a news release. The study evaluated the biosensor’s ability to track lean muscle mass (LLMM) and protein ingestion in patients taking GLP-1s. GLP-1s offer treatment for diabetes and obesity but can lead to the loss of muscle mass.
The system — similar to continuous glucose monitoring (CGM) uses a new method of continuously sensing specific chemistry changes on tiny dermal microsensors. Biolinq’s method uses single-stranded DNA segments (the aptamers) created to specifically identify products of protein breakdown.
Biolinq also develops its sensor technology for the purpose of monitoring glucose. It aims to offer the first intradermal glucose sensor that incorporates activity and sleep information into a single wearable device.
Related: Ancora Heart reaches enrollment milestone in pivotal heart failure device trial
The company describes its initial product as “a wearable biosensor powered by an array of tiny electrochemical sensors that measure glucose levels continuously just beneath the skin’s surface.” It closed a $100 million Series C funding round to support the technology earlier this year.
More about the study results shared by Biolinq
Results demonstrated the effective detection of phenylalanine to continuously monitor protein levels. Findings indicate the stability of the sensor over time, linear performance and minimal sensitivity loss over seven days.
The company says the minimal reduction in sensitivity and limit of detection suggests that the basic principles of operation are confirmed. With improved attachment and blocking, the company believes the sensor could work for a longer period with stronger performance.
Biolinq plans for the next phase of its research to focus on conducting clinical trials to evaluate performance in real-world settings.
“GLP-1 medications have transformed the treatment of diabetes and obesity, but they can also increase the risk of muscle loss,” said Rebecca Gottlieb, VP of Advanced Sensor Technologies at Biolinq and lead author of the study. “While patients are advised to consume more protein to preserve muscle, it’s often difficult to know if they’re getting enough. That is why solutions to bridge this gap by providing real-time feedback are more important than ever — especially for those on GLP-1 therapies, older adults, or anyone managing sarcopenia.”
